KR20220167292A - 중증 급성 호흡기 증후군 치료 방법 - Google Patents

중증 급성 호흡기 증후군 치료 방법 Download PDF

Info

Publication number
KR20220167292A
KR20220167292A KR1020227037111A KR20227037111A KR20220167292A KR 20220167292 A KR20220167292 A KR 20220167292A KR 1020227037111 A KR1020227037111 A KR 1020227037111A KR 20227037111 A KR20227037111 A KR 20227037111A KR 20220167292 A KR20220167292 A KR 20220167292A
Authority
KR
South Korea
Prior art keywords
dantrolene
administering
subject
sars
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037111A
Other languages
English (en)
Korean (ko)
Inventor
아드리안 헤프너
Original Assignee
이글 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이글 파마슈티컬즈 인코포레이티드 filed Critical 이글 파마슈티컬즈 인코포레이티드
Publication of KR20220167292A publication Critical patent/KR20220167292A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227037111A 2020-04-10 2021-04-08 중증 급성 호흡기 증후군 치료 방법 Pending KR20220167292A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008529P 2020-04-10 2020-04-10
US63/008,529 2020-04-10
US202063062623P 2020-08-07 2020-08-07
US63/062,623 2020-08-07
PCT/US2021/026303 WO2021207444A1 (en) 2020-04-10 2021-04-08 Methods of treating severe acute respiratory syndrome

Publications (1)

Publication Number Publication Date
KR20220167292A true KR20220167292A (ko) 2022-12-20

Family

ID=75690705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037111A Pending KR20220167292A (ko) 2020-04-10 2021-04-08 중증 급성 호흡기 증후군 치료 방법

Country Status (11)

Country Link
US (1) US12582633B2 (https=)
EP (1) EP4132516A1 (https=)
JP (1) JP2023521162A (https=)
KR (1) KR20220167292A (https=)
CN (1) CN115916189A (https=)
AU (1) AU2021254415A1 (https=)
BR (1) BR112022020107A2 (https=)
CA (1) CA3174684A1 (https=)
IL (1) IL296518A (https=)
MX (1) MX2022012707A (https=)
WO (1) WO2021207444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605364B2 (en) * 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
US12605364B2 (en) 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
US12582633B2 (en) 2026-03-24
EP4132516A1 (en) 2023-02-15
WO2021207444A1 (en) 2021-10-14
CA3174684A1 (en) 2021-10-14
AU2021254415A1 (en) 2022-10-20
US20230149363A1 (en) 2023-05-18
IL296518A (en) 2022-11-01
CN115916189A (zh) 2023-04-04
BR112022020107A2 (pt) 2022-11-29
MX2022012707A (es) 2023-01-05
JP2023521162A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
KR102233826B1 (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
Van Brummelen et al. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
US20230225988A1 (en) Antiviral use of calixarenes
WO2021188787A1 (en) Method for treatment of coronavirus infection
US20230143775A1 (en) Methods of treating coronavirus infections
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
CN112999235B (zh) 糖基聚醚化合物在制备抗副粘病毒或肠道病毒药物的用途
US20230149364A1 (en) Methods of treating viral infections
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
RU2794315C1 (ru) Способ профилактики или лечения коронавирусной и других острых респираторных вирусных инфекций
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
JP2025172919A (ja) 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
JP2025527908A (ja) 気道感染症を処置するための医薬乾燥粉末組成物および方法
HK40029346B (en) Use of a small molecule inhibitor for treatment of respiratory viral pneumonia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902